Disease:
Acquired Immunodeficiency Syndrome

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA No VIP available GSTM1 non-null N/A N/A N/A
No VIP available CA VA GSTM1 null N/A N/A N/A
No VIP available No VIP available VA NAT2 *5A N/A N/A N/A
No VIP available No VIP available VA NAT2 *5B N/A N/A N/A
No VIP available No VIP available VA NAT2 *6A N/A N/A N/A
No VIP available No VIP available VA NAT2 *6B N/A N/A N/A
No VIP available No VIP available VA NAT2 *7A N/A N/A N/A
No VIP available No VIP available VA NAT2 *7B N/A N/A N/A
No VIP available No VIP available VA NAT2 *14A N/A N/A N/A
No VIP available No VIP available VA NAT2 *14B N/A N/A N/A
No VIP available No Clinical Annotations available VA
rs1045642 NC_000007.13:g.87138645A>G, NC_000007.14:g.87509329A>G, NG_011513.1:g.208920T>C, NM_000927.4:c.3435T>C, NP_000918.2:p.Ile1145=, rs10239679, rs11568726, rs117328163, rs17210003, rs2229108, rs386513066, rs60023214, rs9690664
A > G
SNP
I1145I
No VIP available No Clinical Annotations available VA
rs2233945 NC_000006.11:g.31107361C=, NC_000006.11:g.31107361C>A, NC_000006.12:g.31139584C=, NC_000006.12:g.31139584C>A, NG_021348.1:g.29754C=, NG_021348.1:g.29754C>A, NM_014068.2:c.168-57A>C, NM_014068.2:c.168-57C>A, NM_014069.2:c.-558G>T, NM_014069.2:c.-558T>G, NT_113891.2:g.2622083C=, NT_113891.2:g.2622083C>A, NT_113891.3:g.2621977C=, NT_113891.3:g.2621977C>A, NT_167245.1:g.2404499C=, NT_167245.1:g.2404499C>A, NT_167245.2:g.2398914C=, NT_167245.2:g.2398914C>A, NT_167246.1:g.2455729C=, NT_167246.1:g.2455729C>A, NT_167246.2:g.2450109C=, NT_167246.2:g.2450109C>A, NT_167247.1:g.2489306C=, NT_167247.1:g.2489306C>A, NT_167247.2:g.2483721C=, NT_167247.2:g.2483721C>A, NT_167248.1:g.2403206A=, NT_167248.1:g.2403206A>C, NT_167248.2:g.2397610A=, NT_167248.2:g.2397610A>C, XM_011547844.1:c.*33A>C, XM_011547844.1:c.*33C>A, XM_011547845.1:c.*33A>C, XM_011547845.1:c.*33C>A, rs112468750, rs114324939, rs117539914
C > A
SNP
No VIP available CA No Variant Annotations available
rs2472677 NC_000003.11:g.119518417C>T, NC_000003.12:g.119799570C>T, NG_011856.1:g.24087C>T, NM_003889.3:c.-22-7659C>T, NM_022002.2:c.96-7659C>T, NM_033013.2:c.-22-7659C>T, XM_005247866.1:c.-187-7659C>T, rs57813967
C > T
SNP
No VIP available CA VA
rs3099844 NC_000006.11:g.31448976C=, NC_000006.11:g.31448976C>A, NC_000006.12:g.31481199C=, NC_000006.12:g.31481199C>A, NT_113891.2:g.2958634A=, NT_113891.2:g.2958634A>C, NT_113891.3:g.2958528A=, NT_113891.3:g.2958528A>C, NT_167244.1:g.2763686C=, NT_167244.1:g.2763686C>A, NT_167244.2:g.2813770C=, NT_167244.2:g.2813770C>A, NT_167245.1:g.2734310C=, NT_167245.1:g.2734310C>A, NT_167245.2:g.2728725C=, NT_167245.2:g.2728725C>A, NT_167247.1:g.2828760C=, NT_167247.1:g.2828760C>A, NT_167247.2:g.2823175C=, NT_167247.2:g.2823175C>A, NT_167248.1:g.2742682C=, NT_167248.1:g.2742682C>A, NT_167248.2:g.2737086C=, NT_167248.2:g.2737086C>A, NT_167249.1:g.2779748C=, NT_167249.1:g.2779748C>A, NT_167249.2:g.2780450C=, NT_167249.2:g.2780450C>A, XR_926693.1:n.701G=, XR_926693.1:n.701G>T, XR_953042.1:n.531G=, XR_953042.1:n.531G>T, rs116662199, rs116841198, rs58471066, rs7757186
C > A
SNP
No VIP available No Clinical Annotations available VA
rs72554665 NC_000023.10:g.153760484C>A, NC_000023.10:g.153760484C>G, NC_000023.11:g.154532269C>A, NC_000023.11:g.154532269C>G, NG_009015.2:g.20304G>C, NG_009015.2:g.20304G>T, NM_000402.4:c.1466G>C, NM_000402.4:c.1466G>T, NM_001042351.2:c.1376G>C, NM_001042351.2:c.1376G>T, NP_000393.4:p.Arg489Leu, NP_000393.4:p.Arg489Pro, NP_001035810.1:p.Arg459Leu, NP_001035810.1:p.Arg459Pro, NW_003871103.3:g.1966248C>A, NW_003871103.3:g.1966248C>G, XM_005274657.1:c.1469G>C, XM_005274657.1:c.1469G>T, XM_005274657.2:c.1469G>C, XM_005274657.2:c.1469G>T, XM_005274658.1:c.1379G>C, XM_005274658.1:c.1379G>T, XM_005274658.2:c.1379G>C, XM_005274658.2:c.1379G>T, XM_005277833.1:c.1469G>C, XM_005277833.1:c.1469G>T, XM_005277834.1:c.1379G>C, XM_005277834.1:c.1379G>T, XM_011531132.1:c.*498G>C, XM_011531132.1:c.*498G>T, XP_005274714.1:p.Arg490Leu, XP_005274714.1:p.Arg490Pro, XP_005274715.1:p.Arg460Leu, XP_005274715.1:p.Arg460Pro, XP_005277890.1:p.Arg490Leu, XP_005277890.1:p.Arg490Pro, XP_005277891.1:p.Arg460Leu, XP_005277891.1:p.Arg460Pro
C > A
SNP
R489L
No VIP available No Clinical Annotations available VA
rs8175347
(TA)6 > (TA)5
(TA)6 > (TA)7
(TA)6 > (TA)8
microsatellite
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Alternate Names: 
Synonym
AIDS; AIDS, NOS; AIDS-related complex; Acquired Immune Deficiency Syndrome; Acquired Immuno Deficiency Syndrome; Acquired Immuno-Deficiency Syndrome; Acquired Immuno-Deficiency Syndromes; Acquired Immunodeficiency Syndromes; Acquired human immunodeficiency virus infection syndrome NOS; Acquired immunodeficiency syndrome; Immuno-Deficiency Syndrome, Acquired; Immuno-Deficiency Syndromes, Acquired; Immunodeficiency Syndrome, Acquired; Immunodeficiency Syndromes, Acquired; Immunologic Deficiency Syndrome, Acquired; Syndrome, Acquired Immuno-Deficiency; Syndrome, Acquired Immunodeficiency; Syndromes, Acquired Immuno-Deficiency; Syndromes, Acquired Immunodeficiency
PharmGKB Accession Id: PA443250
External Vocabularies

Curated Information ?

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
No related diseases are available

Publications related to Acquired Immunodeficiency Syndrome: 27

No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342). The Journal of antimicrobial chemotherapy. 2016. Castillo-Mancilla Jose R, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic drug monitoring and pharmacogenetic study. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi. 2016. Tsai Mao-Song, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study). The Journal of antimicrobial chemotherapy. 2015. Bonora S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Predictive value of cytokines and immune activation biomarkers in AIDS-related non-Hodgkin lymphoma treated with rituximab plus infusional EPOCH (AMC-034 trial). Clinical cancer research : an official journal of the American Association for Cancer Research. 2015. Epeldegui Marta, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2. Pharmacogenetics and genomics. 2014. McDonagh Ellen M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
HCP5 genetic variant (RS3099844) contributes to Nevirapine-induced Stevens Johnsons Syndrome/Toxic Epidermal Necrolysis susceptibility in a population from Mozambique. European journal of clinical pharmacology. 2014. Borgiani Paola, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Allele-specific methylation occurs at genetic variants associated with complex disease. PloS one. 2014. Hutchinson John N, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Mitochondrial DNA Variation and Changes in Adiponectin and Endothelial Function in HIV-Infected Adults After Antiretroviral Therapy Initiation. AIDS research and human retroviruses. 2013. Hulgan Todd, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The Dual Role of Pharmacogenetics in HIV Treatment: Mutations and Polymorphisms Regulating Antiretroviral Drug Resistance and Disposition. Pharmacological reviews. 2012. Michaud Veronique, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Very important pharmacogene summary for VDR. Pharmacogenetics and genomics. 2012. Poon Audrey H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment. Pharmacogenomics. 2012. Li Jing, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Severe atazanavir-associated hyperbilirubinemia revealing Canton G6PD deficiency in an Asian HIV-infected patient. AIDS (London, England). 2012. Javelle Emilie, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. The Journal of infectious diseases. 2011. Lubomirov Rubin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Use of biological knowledge to inform the analysis of gene-gene interactions involved in modulating virologic failure with efavirenz-containing treatment regimens in ART-naïve ACTG clinical trials participants. Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing. 2011. Grady Benjamin J, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Population Pharmacokinetic modelling of the association between 63396C->T Pregnane-X-Receptor (PXR) polymorphism and unboosted atazanavir clearance. Antimicrobial agents and chemotherapy. 2010. Schipani Alessandro, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. The Journal of infectious diseases. 2010. Ribaudo Heather J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A genetic polymorphism of matrix metalloproteinase 9 (MMP-9) affects the changes in circulating MMP-9 levels induced by highly active antiretroviral therapy in HIV patients. The pharmacogenomics journal. 2009. Demacq C, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2008. Siccardi Marco, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Duffy antigen receptor for chemokines mediates trans-infection of HIV-1 from red blood cells to target cells and affects HIV-AIDS susceptibility. Cell host & microbe. 2008. He Weijing, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. Nature medicine. 2008. Ahuja Sunil K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Novel association in chromosome 4q27 region with rheumatoid arthritis and confirmation of type 1 diabetes point to a general risk locus for autoimmune diseases. American journal of human genetics. 2007. Zhernakova Alexandra, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
HIV/AIDS vaccines: 2007. Clinical pharmacology and therapeutics. 2007. Robinson H L. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Association between AIDS disease progression rates and the Fok-I polymorphism of the VDR gene in a cohort of HIV-1 seropositive patients. The Journal of steroid biochemistry and molecular biology. 2004. Nieto Gema, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Tissue glucocorticoid resistance/hypersensitivity syndromes. The Journal of steroid biochemistry and molecular biology. 2003. Kino Tomoshige, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Host genetic background at CCR5 chemokine receptor and vitamin D receptor loci and human immunodeficiency virus (HIV) type 1 disease progression among HIV-seropositive injection drug users. The Journal of infectious diseases. 2001. Barber Y, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Prospective evaluation of detoxification pathways as markers of cutaneous adverse reactions to sulphonamides in AIDS. Pharmacogenetics. 2000. Wolkenstein P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Apparent hemolysis in an AIDS patient receiving trimethoprim/sulfamethoxazole: case report and literature review. The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians. 1996. Reinke C M, et al. PubMed